EGFR and neoplasm: As more molecular imaging probes enter late-phase clinical trials, we compared the performance of a fluorescently labeled epidermal growth factor receptor (EGFR) antibody, panitumumab-IRDye800, in different tumor types to elucidate intrinsic and extrinsic parameters that influence tumor imaging and inform clinical decisions.